SCHEMBL7258541

SCHEMBL7258541

Fc1cccc(Nc2ncc(F)c(Nc3ccc4ncccc4c3)n2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 10/20 0.58
AURKA O14965 5/20 0.57
KDR P35968 2/20 0.57
CDK1 P06493 2/20 0.54
CDK2 P24941 2/20 0.54
ITK Q08881 2/20 0.54
BTK Q06187 2/20 0.54
PLK4 O00444 1/20 0.54
PDPK1 O15530 1/20 0.54
JAK2 O60674 1/20 0.54
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
NTRK1 P04629 1/20 0.54
INSR P06213 1/20 0.54
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54
FES P07332 1/20 0.54
CSF1R P07333 1/20 0.54
LYN P07948 1/20 0.54
IGF1R P08069 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657592 0.89 SYK (0.76) SYKAURKAMAPK8AURKB
SCHEMBL19675893 0.89 SYK (0.55) SYKAURKAKDRITKBTK
SCHEMBL15584970 0.89 ULK1 (0.51) SYKAURKAKDRULK1ULK2
SCHEMBL7258580 0.84 SYK (0.52) SYKAURKAKDRCDK1CDK2
SCHEMBL4000667 0.84 JAK3 (0.61) SYKAURKAKDRCDK1CDK2
SCHEMBL15585219 0.81 ULK1 (0.42) SYKAURKAKDRSTK17AULK1
SCHEMBL655954 0.79 GRM4 (0.50) SYKAURKAKDRCDK1ERBB4
SCHEMBL4002573 0.79 SYK (0.62) SYKAURKAKDRCDK1CDK2
SCHEMBL6210503 0.78 PTK2 (0.54) SYKAURKAKDRCDK1CDK2
SCHEMBL7258709 0.76 KDR (0.54) SYKAURKAKDRCDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003030909-A1 2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-17 WO disclosed